May 5 (Reuters) - Cytokinetics said on Tuesday its experimental heart disease drug significantly improved symptoms of a genetic heart condition in a late-stage trial. Shares of the company were up 13.

Lifestyle, environment, and genetics can shape heart disease risk, but a new study from UConn researchers explores how ...

Many risk factors for cardiovascular conditions exist, including inherited factors. Now, a validation study suggests a new ...

From preeclampsia to menopause, a Yale cardiologist explains how women’s life stages shape heart disease risk—and what to ask ...

It seems like there's scary news about heart health everywhere. On highway billboards, in news alerts about celebrities and ...

Swedish registry follow-up of >5.3 million pre-pandemic and >5.5 million pandemic adults linked death of a partner, child, ...

Heart disease has remained the leading cause of death for men in the United States for the last century. It’s also the second leading ...

Lorenzo was a vibrant broadcaster, a kind and passionate colleague, a beloved voice on Western Cape airwaves, but more than ...

You can’t predict when or how you’re going to die, but you may be able to estimate what you’re more likely to die of ...

A new study suggests that lipoprotein(a) acts as a driver of residual cardiovascular risk and proposes a threshold Lp(a) to ...

Beverly Hills Cardiologist Publishes Book Addressing Female Heart Attack Signs and Symptoms Beverly Hills, Aruba - May ...

Six-year-old Dominic Spicher, who has congenital heart disease, will see his dream fulfilled. He meets the Savannah Bananas ...